Oncology (all articles)
Guidance | Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology.
13 Oct, 2022 | 13:46h | UTC
Cohort Study | Association of long-term oncologic prognosis with minimal access breast surgery vs. conventional breast surgery.
13 Oct, 2022 | 13:38h | UTC
Commentary on Twitter
A single-center retrospective cohort study found that the long-term outcomes of minimal-access breast surgery are not significantly different from those of conventional #BreastSurgery in patients with stage 0-III #BreastCancer. https://t.co/SMQWCNSa4X
— JAMA Surgery (@JAMASurgery) October 6, 2022
Review | Permissive cardiotoxicity: the clinical crucible of cardio-oncology.
13 Oct, 2022 | 13:35h | UTCPermissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology – JACC: CardioOncology
RCT | Effect of colonoscopy screening on risks of colorectal cancer and related death.
11 Oct, 2022 | 13:42h | UTCEffect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
In gold-standard trial, invitation to colonoscopy reduced cancer incidence but not death – STAT
New study examines the effectiveness of colonoscopies – CNN
Consensus recommendations for screening and managing childhood cancer survivors at risk for cardiomyopathy.
11 Oct, 2022 | 13:35h | UTCRelated:
Cardiometabolic Comorbidities in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review
Brazilian Cardio-oncology Guideline – 2020 – Arquivos Brasileiros de Cardiologia
RCT | Toripalimab plus chemotherapy for patients with treatment-naive advanced non–small-cell lung cancer.
11 Oct, 2022 | 13:31h | UTC
Retrospective cohort | Outcomes in relapsed neuroblastoma treated with Irinotecan / Temozolomide / Dinutuximab / GM-CSF.
11 Oct, 2022 | 13:30h | UTC
Consensus on re-irradiation: definition, reporting, and clinical decision making.
7 Oct, 2022 | 14:16h | UTC
Guideline Summary | Recommendations for care of survivors of head and neck cancer.
7 Oct, 2022 | 14:15h | UTCRecommendations for Care of Survivors of Head and Neck Cancer – JAMA (free for a limited period)
Original Guideline: Head and neck cancer survivorship consensus statement from the American Head and Neck Society – Laryngoscope Investigative Otolaryngology
Related:
American Cancer Society Head and Neck Cancer Survivorship Care Guideline
RCT | Switch to fulvestrant and palbociclib in breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy.
7 Oct, 2022 | 14:12h | UTCSwitch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial – The Lancet Oncology (free for a limited period)
Review | Clinical advances and ongoing trials on mRNA vaccines for cancer treatment.
7 Oct, 2022 | 14:10h | UTCClinical advances and ongoing trials on mRNA vaccines for cancer treatment – The Lancet Oncology (free for a limited period)
Secondary prevention of cervical cancer | ASCO resource–stratified guideline update.
6 Oct, 2022 | 13:44h | UTC
Podcast | Oncologic Emergencies: from cord compression to tumor lysis syndrome.
6 Oct, 2022 | 13:41h | UTC#358 Oncologic Emergencies with Dr. Aditi Singh – The Curbsiders
Consensus Paper | Corticosteroids in oncology: use, overuse, indications, contraindications.
5 Oct, 2022 | 13:52h | UTC
Podcast | Polyps, polypectomy & surveillance.
4 Oct, 2022 | 14:32h | UTCPolyps, polypectomy & surveillance with Dr. Jennifer Maranki – The Curbsiders
Cohort Study | Adenoma detection rate after a positive FIT is linked to the risk of interval postcolonoscopy colorectal cancer.
4 Oct, 2022 | 14:31h | UTCAdenoma Detection Rate and Risk for Interval Postcolonoscopy Colorectal Cancer in Fecal Immunochemical Test–Based Screening: A Population-Based Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentaries:
Adenoma Detection Rate Tied to CRC Risk After Positive FIT – HealthDay
Commentary on Twitter
New from @ErasmusMC: endoscopists performing colonoscopy in FIT-based screening programs should aim for higher ADRs compared w/ programs that use colonoscopy as primary screening intervention: https://t.co/Fob1gxXF1i pic.twitter.com/y6qoAkOrT9
— Annals of Int Med (@AnnalsofIM) September 30, 2022
RCT | Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer.
3 Oct, 2022 | 13:42h | UTCCommentary: Selumetinib Does Not Improve CR Rate in Differentiated Thyroid Cancer – Cancer Therapy Adviser
Commentary on Twitter
❎ ASTRA trial: Radioactive iodine ± selumetinib doesn't improve remission rates for high-risk #thyroidcancer
✅ Postoperative pathologic risk stratification identified pts at risk of primary treatment failurehttps://t.co/kvakaMXtDh#JCO #thycsm @MSKCancerCenter pic.twitter.com/mvQwgzIjWh— Journal of Clinical Oncology (@JCO_ASCO) March 16, 2022
RCT | Adjuvant Nivolumab plus Ipilimumab vs. Nivolumab alone in patients with resected Stage IIIB-D or Stage IV melanoma.
30 Sep, 2022 | 12:33h | UTC
Cohort Study | A clinical calculator for rectal cancer can estimate recurrence after neoadjuvant therapy with or without surgery.
30 Sep, 2022 | 12:34h | UTCInvited Commentary: A Clinical Calculator in the Era of Nonoperative Management for Rectal Cancer—How Should We Intensify or Deescalate Surveillance? – JAMA Network Open
Systematic Review | Impact of residual disease in women with advanced epithelial ovarian cancer after primary surgery.
30 Sep, 2022 | 12:28h | UTC
RCT | Pembrolizumab vs. placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer.
29 Sep, 2022 | 13:22h | UTCPembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Adjuvant Pembrolizumab in Patients With Completely Resected Stage IB to IIIA NSCLC – The ASCO Post
Adjuvant Pembrolizumab Prolongs DFS in Resected Non-Small Cell Lung Cancer – Cancer Therapy Advisor
Commentary on Twitter
New Research in @TheLancetOncol—Pembrolizumab improves disease-free survival vs placebo in completely resected, PD-L1-unselected, stage IB–IIIA #NSCLC
From Prof Mary O’Brien & colleagues https://t.co/Azqb8WTOwp pic.twitter.com/141bhAPtg5
— The Lancet Respiratory Medicine (@LancetRespirMed) September 13, 2022
ASCO Guideline Update | Poly(ADP-Ribose) Polymerase inhibitors in the management of ovarian cancer.
28 Sep, 2022 | 13:44h | UTC
RCT | First-Line Serplulimab vs. placebo added to chemotherapy in patients with extensive-stage small cell lung cancer.
28 Sep, 2022 | 13:41h | UTCEffect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual Abstract
RCT | A comprehensive geriatric assessment may improve the quality of life in older people starting anticancer treatment.
27 Sep, 2022 | 13:16h | UTCInvited Commentary: Integrating what matters to patients in the care of older adults with cancer – The Lancet Health Longevity
Related:
Commentary from the author on Twitter
Excited that our #INTEGERATE Study RCT on the benefits of comprehensive geriatric assessment and integrated oncogeriatric care has been published. Thank you for your support! @easternhealthau @EHCSMonash @Prof_IanD @ParentePhillip #GeriOnc @LancetLongevity https://t.co/F0ikcg9hnK
— Kheng Soo (@KhengSoo1) August 22, 2022
M-A | Addition of androgen receptor targeted agents to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer.
27 Sep, 2022 | 13:02h | UTC